Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Nipro Pharma Forms Capital Tie-Up with Vietnam’s Mekophar
November 16, 2016
- Sawai Might See Teva-Takeda JV Impact on Distribution Channel: President
November 15, 2016
- Ethical Drug Sales Down 5.6% in September: Crecon Report
November 15, 2016
- Pace of Generic Substitution Slowing at Pharmacies: Sawai President
November 15, 2016
- Regenerative Medicine Market to Expand to 142.1 Billion Yen in 2030: Fuji Keizai
November 11, 2016
- Opdivo Significantly Prolongs OS in Gastric Cancer Patients in PIII Study: Ono
November 11, 2016
- Takecab Most Promoted Drug in September: Anterio
November 11, 2016
- Top 4 Wholesalers See Lower Sales in April-September If Hep C Meds Excluded
November 11, 2016
- Enrollment Completed for PIII Adcetris Study for Mature T-Cell Lymphoma: Takeda
November 10, 2016
- Nippon Shinyaku’s DMD Med Gets Fast Track Status in US
November 10, 2016
- Kipres Generics Earn Bronchial Asthma Indication in Droves
November 10, 2016
- MSD to Seek Keytruda Listing after Adding Lung Cancer Indication
November 10, 2016
- Takeda to Collaborate with 2 Universities on Application of Miniature Liver Technology to Drug Discovery Research
November 10, 2016
- Kipres AG’s Market Penetration Faster than Expected: Kyorin President
November 9, 2016
- Teva Takeda Pharma “Not a Threat” at Present: Nichi-Iko Pres. Tamura
November 9, 2016
- BIKEN, Mitsubishi Tanabe to Form Vaccine JV Next May
November 8, 2016
- Current Drug Pricing System Became Unfit for New Drugs Like Opdivo: Ono Chief
November 8, 2016
- Ono's Revenue and Profits Soar as Opdivo Sales Jump 1,714%
November 8, 2016
- MSD’s New Dual Oral Hep C Therapy to Challenge Harvoni; Effective Regardless of Resistance Mutations, Renal Impairment
November 8, 2016
- Japan Diabetes Market Likely to Grow 40% by 2024: Fuji Keizai
November 7, 2016
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…